Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
12 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-presents-genetic-toxicology-safety-data-on-api-in-igc-ad1-at-the-2025-gene-1026391
24 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-welcomes-strategic-investment-from-advisors-1019018
21 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-welcomes-industry-leaders-to-advisory-board-supporting-alzheimers-innovati-1017381
08 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-expands-calma-alzheimers-phase-2-trial-with-prestigious-research-site-at-b-1012113
01 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-announces-calma-phase-2-trial-expansion-with-the-addition-of-miami-jewish-1008215
26 Mar 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharmas-phase-2-clinical-trial-interim-data-demonstrates-significant-reduction-in-1005488
ABOUT THIS PAGE